The original description of the ischaemic penumbra asserted that both cerebral blood flow and metabolism would be required to monitor therapeutic intervention in acute ischaemic stroke. However, imaging in stroke trials has predominantly used biomarkers of infarction or perfusion-weighted signal to identify the pathophysiological processes that occur. This approach has neither identified novel treatment targets, nor been shown to consistently select patients who might benefit from interven...